v3.26.1
Warrants
6 Months Ended
Jun. 30, 2026
Warrants  
Warrants

Note 7 – Warrants

Public Warrants and Private Placement Warrants

The table below provides a summary of the outstanding Public and Private Placement Warrants classified as a liability.

  ​ ​ ​

June 30, 2026

  ​ ​ ​

December 31, 2025

Public Warrants

14,425,294

13,958,836

Private Placement Warrants

4,908,009

5,374,467

Each whole Warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per share, subject to customary adjustments. Only whole Warrants are exercisable. The Warrants became exercisable on January 7, 2022 and will expire on December 8, 2026.

None of the Private Placement Warrants are redeemable by the Company so long as they are held by the initial purchasers of the Private Placement Warrants or their permitted transferees. The table below provides the fair value of warrant liabilities at:

  ​ ​ ​

June 30, 2026

  ​ ​ ​

December 31, 2025

Fair value of warrant liabilities

$

1,990

$

13,881

The table below provides the gain (loss) recognized in connection with changes in fair value of warrant liabilities at:

Three Months Ended June 30, 

Six Months Ended June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

2026

  ​ ​ ​

2025

Gain (Loss) recognized associated with warrant liabilities

$

2,250

$

(3,216)

$

11,891

$

2,663

There have been no changes to the terms of the Public or Private Placement Warrants disclosed in the 2025 Form 10-K.

Pre-Funded Warrants and Common Warrants

In January 2026, the Company issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 5,807,018 shares of common stock and warrants (the “Common Warrants”) to purchase up to an aggregate of 45,614,036 shares of common stock. As of June 30, 2026, there were no Pre-Funded Warrants outstanding and there were Common Warrants to purchase an aggregate of 45,614,036 shares of common stock outstanding. The Common Warrants are classified in equity and are not measured at fair value and are not remeasured each reporting period. See Note 8 – Stockholders’ Equity for additional information.